A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

STUDY OVERVIEW

This study sponsored by Janssen aims to assess whether milvexian, in combination with standard-of-care, is more effective than placebo in reducing the risk of major adverse cardiovascular events (MACE), encompassing cardiovascular death, myocardial infarction, and ischemic stroke.

STUDY GOALS

The study aims to determine whether the addition of milvexian to standard-of-care treatment reduces the risk of major adverse cardiovascular events (MACE) compared to placebo in individuals at risk for cardiovascular events.

LOCATION

El Paso, Texas: Texas Tech University Health Sciences Center

INCLUSION CRITERIA

  • Participants must have experienced a recent heart event consistent with acute coronary syndrome (ACS) and elevated cardiac biomarkers.

  • Participants should have at least two of the following risk factors: age 65 or older, diabetes, history of prior heart attack, multiple coronary artery blockages, previous heart surgery, history of peripheral artery or cerebrovascular disease, conservative treatment post-heart event, or high-risk angiographic features.

  • Female participants of childbearing age must have a negative pregnancy test and agree not to become pregnant during the study.

exclusion criteria

  • Excluded conditions include Type 2 heart attacks, planned heart surgeries or interventions post-randomization, need for long-term blood thinners, or conditions predisposing to increased bleeding risk.

For more information, visit ClinicalTrials.gov.